Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
AI C3.ai
- 21.390
- +0.340+1.62%
Trading Apr 1 15:42 ET
2.84BMarket Cap-9.59P/E (TTM)
21.570High20.650Low2.38MVolume21.210Open21.050Pre Close50.38MTurnover2.05%Turnover RatioLossP/E (Static)132.74MShares45.08052wk High3.30P/B2.49BFloat Cap18.85052wk Low--Dividend TTM116.38MShs Float183.900Historical High--Div YieldTTM4.37%Amplitude10.160Historical Low21.128Avg Price1Lot Size
C3.ai Key Stats
Quarterly+Annual
YOY
| (Q3)Jan 31, 2025 | (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 43.61%-22.02M | 20.37%-38.69M | 104.32%8.04M | 46.10%-62.36M | -21.11%21.34M | 24.76%-39.05M | 7.60%-48.59M | 110.29%3.94M | -33.81%-115.69M | 305.55%27.05M |
| Net income from continuing operations | -10.42%-80.2M | 5.46%-65.97M | 2.38%-62.83M | -4.04%-279.7M | -12.27%-72.93M | -14.99%-72.63M | -1.35%-69.78M | 10.45%-64.36M | -39.97%-268.84M | -11.19%-64.96M |
| Depreciation and amortization | -3.88%3.12M | -6.04%2.97M | 2.06%3.12M | 108.92%12.72M | 14.80%3.25M | 284.95%3.25M | 232.35%3.16M | 109.17%3.06M | 17.30%6.09M | 98.11%2.83M |
| Other non cash items | 69.07%-1.29M | 16.51%-7.18M | -38.80%183K | -88.40%840K | 316.00%13.31M | -225.03%-4.17M | -596.36%-8.6M | -84.59%299K | 80.08%7.24M | 129.06%3.2M |
| Change In working capital | 69.22%-6.3M | 3.37%-29.49M | -6.73%16.82M | 107.24%5.23M | -10.07%38.19M | 57.99%-20.48M | 22.68%-30.52M | 168.26%18.03M | -283.57%-72.17M | 742.81%42.47M |
| -Change in receivables | 27.56%-21.97M | 2.77%-20.01M | -183.52%-10.04M | 108.29%4.52M | 377.50%43.41M | 38.04%-30.33M | -49.80%-20.58M | 1,396.33%12.02M | -285.12%-54.52M | 174.57%9.09M |
| -Change in prepaid assets | 195.06%2.58M | 3.20%-3.6M | -47.43%1.6M | 656.94%3.21M | -8.12%6.59M | 40.23%-2.71M | 39.22%-3.72M | 4.85%3.05M | 96.05%-576K | 9.79%7.17M |
| -Change in payables and accrued expense | 2,789.93%20.09M | -183.58%-13.8M | 3,131.18%18.28M | -1.34%-19.1M | -326.23%-14.33M | -82.91%695K | 42.21%-4.87M | 97.10%-603K | -142.00%-18.85M | -84.88%6.33M |
| -Change in other current liabilities | -137.51%-4.17M | 1,415.24%12.43M | -46.07%5.64M | 730.74%25.49M | -55.69%4.86M | 244.89%11.11M | -150.67%-945K | 598.71%10.46M | 134.59%3.07M | 152.56%10.97M |
| -Change in other working capital | -478.00%-2.84M | -1,010.10%-4.51M | 119.38%1.34M | -587.93%-8.89M | -126.30%-2.34M | -91.00%750K | 96.89%-406K | -25.80%-6.89M | 95.05%-1.29M | 186.41%8.91M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 43.61%-22.02M | 20.37%-38.69M | 104.32%8.04M | 46.10%-62.36M | -21.11%21.34M | 24.76%-39.05M | 7.60%-48.59M | 110.29%3.94M | -33.81%-115.69M | 305.55%27.05M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 201.93%12.37M | 290.24%22.64M | 51.00%-41.55M | -211.13%-66.62M | 146.04%25.99M | -95.23%4.1M | -110.72%-11.9M | -5.38%-84.8M | -81.09%59.95M | -134.91%-56.44M |
| Capital expenditure reported | --0 | --0 | --0 | -175.00%-2.75M | --0 | --0 | ---1.25M | -50.00%-1.5M | -100.00%-1M | --0 |
| Net PPE purchase and sale | 94.05%-362K | 84.60%-815K | 91.85%-924K | 64.19%-25.26M | 76.39%-2.54M | 69.24%-6.09M | 78.34%-5.29M | 27.02%-11.34M | -1,760.14%-70.52M | -568.59%-10.75M |
| Net investment purchase and sale | 25.04%12.74M | 537.91%23.45M | 43.55%-40.63M | -129.37%-38.61M | 162.43%28.52M | -90.36%10.19M | -103.95%-5.36M | -12.55%-71.96M | -59.08%131.46M | -127.98%-45.69M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 201.93%12.37M | 290.24%22.64M | 51.00%-41.55M | -211.13%-66.62M | 146.04%25.99M | -95.23%4.1M | -110.72%-11.9M | -5.38%-84.8M | -81.09%59.95M | -134.91%-56.44M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 2,566.73%13.47M | 14.96%3.51M | -92.65%182K | 1,718.68%11.29M | 71.13%5.26M | 158.86%505K | 213.99%3.06M | 127.87%2.48M | -89.13%621K | 122.73%3.07M |
| Net common stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | 1,148.03%15.18M | 13.00%6.35M | -67.41%3.13M | 224.22%24.51M | 55.47%8.08M | 108.93%1.22M | 709.06%5.62M | 782.70%9.6M | -63.68%7.56M | 250.67%5.2M |
| Net other financing activities | -140.37%-1.71M | -10.67%-2.84M | 58.63%-2.95M | -90.49%-13.22M | -32.85%-2.82M | 50.63%-711K | ---2.57M | ---7.12M | -6,509.52%-6.94M | ---2.13M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 2,566.73%13.47M | 14.96%3.51M | -92.65%182K | 1,718.68%11.29M | 71.13%5.26M | 158.86%505K | 213.99%3.06M | 127.87%2.48M | -89.13%621K | 122.73%3.07M |
| Net cash flow | ||||||||||
| Beginning cash position | -17.17%133.84M | -33.16%146.39M | -39.57%179.71M | -15.64%297.4M | -60.73%127.13M | -44.40%161.58M | -6.76%219.01M | -15.64%297.4M | 203.23%352.52M | 48.82%323.71M |
| Current changes in cash | 111.09%3.82M | 78.16%-12.55M | 57.49%-33.33M | -113.49%-117.68M | 299.84%52.59M | -204.09%-34.45M | -203.04%-57.43M | 33.37%-78.39M | -123.33%-55.12M | -119.49%-26.31M |
| End cash Position | 8.29%137.66M | -17.17%133.84M | -33.16%146.39M | -39.57%179.71M | -39.57%179.71M | -60.73%127.13M | -44.40%161.58M | -6.76%219.01M | -15.64%297.4M | -15.64%297.4M |
| Free cash flow | 50.41%-22.38M | 28.34%-39.51M | 179.96%7.12M | 51.73%-90.37M | 15.35%18.81M | 37.04%-45.14M | 28.43%-55.13M | 83.75%-8.9M | -106.28%-187.21M | 210.38%16.3M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
